MALVERN, Pa. and TORONTO, Oct. 4, 2024 /PRNewswire/ - Neuronetics, Inc. (NASDAQ: STIM) ("Neuronetics") and Greenbrook TMS Inc. (OTCMKTS: GBNHF) ("Greenbrook") today announced that the Ontario Superior Court of Justice (Commercial List) (the "Court") has granted an interim order (the "Interim Order") in connection with the previously announced statutory plan of arrangement under section 182 of the Business Corporations Act (Ontario) (the "Plan of Arrangement"), pursuant to which, subject to the satisfaction ...

MALVERN, Pa., Sept. 25, 2024 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, announced that Health Care Service Corporation (HCSC) has expanded access to TMS (transcranial magnetic stimulation) for adolescents 15 and older with major depressive disorder (MDD). This policy parallels the recent clearance by the Food and Drug Administra ...

Neuronetics, Inc. (STIM) recently announced that additional payors have updated the coverage of TMS (transcranial magnetic stimulation). This upgrade is aimed at reducing the access barriers for patients with major depressive disorder (MDD). This expanded access will help people receive treatments, such as the company's NeuroStar TMS therapy, earlier in their treatment regimen. STIM Stock Likely Trend Following the News Following the news, STIM stock fell 1.8% to 93 cents on Friday. However, the company is ...

MALVERN, Pa., Sept. 19, 2024 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, announced that additional payors have updated their TMS (transcranial magnetic stimulation) coverage to reduce access barriers for patients with major depressive disorder (MDD). This expanded access allows people to receive treatment such as the Company's Ne ...

MALVERN, Pa., Sept. 16, 2024 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, announced enhancements to its NeuroStar Advanced Therapy and proprietary TrakStar® patient data management software, introducing a range of new features aimed at improving patient communication, streamlining clinical data capture, and strengthening cybersecu ...

MALVERN, Pa., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, is proud to shine a light on the powerful stories shared through the NeuroStar Voices Portal in recognition of Suicide Prevention Month. Launched last year, the portal has become a vital platform for individuals to share their journeys of battling depression ...

文章核心观点 - 纽罗内蒂克斯公司(Neuronetics, Inc.)拟以全股票交易的方式收购磁神经刺激公司Greenbrook TMS Inc.[1][2][3] - 此次收购将为美国患有心理健康疾病的患者提供创新的护理服务[1] - 收购后,公司将通过整合Greenbrook的成熟的实践运营和支持能力以及Neuronetics的先进的NeuroStar平台,增强Greenbrook现有地点和任何希望为其患者提供NeuroStar的医疗服务提供商的护理[2] 收购的战略利益 - 建立一家垂直整合的公司,能够大规模提供经颅磁刺激(TMS)治疗[4] - 通过统一品牌的营销努力,提高NeuroStar产品在患者、照顾者和医疗服务提供商中的知名度[5] - 在所有Greenbrook网点实施NeuroStar最佳实践[5] - 扩大培训机会,提高将药物管理和Spravato治疗与NeuroStar结合的能力,并获得改善业务运营的集中服务[6] 收购的财务利益 - 收购将增加收入规模,并提供强劲的增长轨迹[8] - 预计到2025财年和2026财年,合并业务的收入将实现中个位数的同比增长[8] - 通过优化营销支出和后台运营,预计将实现至少1500万美元的年度成本节约[9] - 预计到2025财年全年将实现正的经调整EBITDA和现金流,不包括与交易相关的一次性成本[9] - 由于Greenbrook的债务被转换为普通股,加上收购后的业务规模,合并公司可以利用改善的资产负债表执行长期增长战略[10] 行业前景 - 根据Mordor Intelligence的报告,全球焦虑障碍和抑郁治疗市场规模预计将从2024年的215亿美元增长到2029年的279亿美元,复合年增长率为5.3%[11][12] - 抑郁症治疗市场的增长潜力为Neuronetics的业务发展和收入增长提供了机遇[13] 重要动态 - 5月,Neuronetics宣布与Transformations Care Network(一家心理健康服务提供商)扩大商业合作[14] - 4月,Neuronetics宣布NeuroStar Advanced Therapy获得FDA 510(k)认证,可用于治疗15-21岁青少年的主要抑郁障碍[15]

Neuronetics, Inc. (STIM) recently announced a definitive agreement with Greenbrook TMS Inc. to acquire its outstanding common shares in an all-stock transaction. Following the merger's completion, Greenbrook will be able to improve its existing sites to provide the benefits of NeuroStar to any practice across the country. It will do so using Neuronetics' innovative NeuroStar platform as well as its education and training expertise. The merger agreement will help Neuronetics strengthen its position in the me ...

Neuronetics (STIM) reported a net loss of 33 cents per share in second-quarter 2024, wider than the year-ago quarter's reported loss of 17 cents. The figure also lagged the Zacks Consensus Estimate of a loss of 27 cents per share. Q2 Revenues Consolidated revenues amounted to $16.5 million, down 6.3% from $17.6 million recorded in the second quarter of 2023. The figure missed the Zacks Consensus Estimate by 12.2%. Segments in Detail Neuronetics reports under two primary markets, based on the geographic loca ...

财务表现 - 第二季度2024年收入为1650万美元，同比下降7%[3] - 毛利率为74%，同比增加约150个基点[11] - 运营费用为2070万美元，同比增加3%[12] - 净亏损为980万美元，每股亏损0.33美元[13] - 公司2024年上半年总收入为33,867千美元，同比增长2.2%[33] - 2024年上半年毛利为25,267千美元，毛利率为74.6%[33] - 2024年上半年销售及营销费用为23,943千美元，同比增长2.0%[33] - 2024年上半年研发费用为4,585千美元，同比下降11.0%[33] - 2024年上半年EBITDA为-14,251千美元[37] - 2024年第二季度EBITDA为-7,952千美元[37] - 2024年上半年每股亏损为0.59美元[33] 业务表现 - 美国NeuroStar Advanced Therapy系统收入为400万美元，同比下降11%[9] - 美国治疗会话收入同比下降5%[10] - 与Greenbrook TMS签署最终合并协议，将成为美国领先的精神健康护理提供商之一[16,17] - 主要保险公司扩大了青少年抑郁症TMS治疗的承保范围[18] - 推出全国性的"Better Me Provider"计划，提高患者护理和可及性[19] 财务状况 - 现金及现金等价物为4260万美元[15] - 2024年6月30日现金及现金等价物余额为42,642千美元[34] - 2024年6月30日总资产为96,813千美元，较2023年12月31日下降16.4%[34] - 2024年6月30日总负债为77,427千美元，较2023年12月31日下降5.2%[34]